Antipsychotic medication in first-episode psychosis: An RCT to assess the risk-benefit ratio

首发精神病中的抗精神病药物：评估风险收益比的随机对照试验

• 批准号: nhmrc : 1064704
• 负责人: A/Pr Alexander Fornito
• 金额: $ 76.09万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antipsychotic-medication-first-benefit-ratio/455133
• 关键词: Antipsychotic; medication; first; episode; psychosis

There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.

人们越来越强调在精神疾病的早期进行干预。早期干预的一个基本原则是“不造成伤害”，益处必须大于治疗的风险。虽然抗精神病药物对大多数首发精神病（FEP）患者的阳性症状是非常有效和循证的治疗形式，但它有风险。这项研究有可能确定抗精神病药物是否应该作为FEP的初始治疗选择。